|
Bipolar Disorder
|
0.110 |
Biomarker
|
disease |
BEFREE |
Individuals with BD in a euthymic state have reduced P50 sensory gating and reduced P100 amplitudes compared with healthy controls.
|
29981961 |
2018 |
|
Bipolar Disorder
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis.
|
27890468 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes.
|
29632382 |
2018 |
|
Adolescent idiopathic scoliosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis.
|
27890468 |
2017 |
|
Reticulocyte count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i> expression of the TRAF6 protein, phosphorylated transcription factor p65 and phosphorylated p100 in myeloma cell lines was induced by MSCs from patients with MM.
|
28789366 |
2017 |
|
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The molecular mechanism of p100 degradation has implications in multiple myeloma, a disease with constitutive activation of the noncanonical NF-κB pathway.
|
23211527 |
2012 |
|
Multiple Myeloma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
C-terminal truncations of the NFKB2 p100 gene product have been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymphomas and myelomas.
|
10713675 |
2000 |
|
Optic Neuritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The rates of change in the absence of optic neuritis (ON) for minimal VEP intervals of ≥3 months between baseline and last follow-up were +1.951 ms/y (n = 101 eyes; SD = 6.274; <i>p</i> = 0.012) for the P100 latencies and -2.149 µV/y (n = 64 eyes; SD = 5.013; <i>p</i> = 0.005) for the P100-N140 amplitudes.
|
31796527 |
2020 |
|
Multiple Sclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
To examine the thiol-disulphide homeostasis during an optic neuritis episode in patients with multiple sclerosis and the relationship between this homeostasis and P100 wave latency.
|
30506120 |
2019 |
|
Multiple Sclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In a multivariable regression model, age and P100 latency were significant parameters for affecting AA in patients with MS (<i>p</i> < .001 and <i>p</i> = .001).
|
31172825 |
2019 |
|
Optic Neuritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
To examine the thiol-disulphide homeostasis during an optic neuritis episode in patients with multiple sclerosis and the relationship between this homeostasis and P100 wave latency.
|
30506120 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Moreover, we validated p100 as a direct target of miR-320a, a tumor suppressing microRNA repressing lung cancer cell migration.
|
29159900 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
|
28190248 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, these findings identify specific roles for p100 and p105 signaling in defining DLBCL molecular subtypes and posit MYD88/p100 signaling as a regulator for B-cell activation.
|
28368397 |
2017 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
|
28190248 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Activation of BR3 in DLBCL induces recruitment and degradation of tumor necrosis factor receptor-associated factor 3, which results in NIK kinase accumulation, IκBα phosphorylation, and NF-κB p100 processing, thereby resulting in continuous activation of both NF-κB pathways in DLBCL cells, leading to autonomous lymphoma cell growth and survival.
|
20889926 |
2011 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Inhibiting RelB in aggressive androgen-independent PC-3 cells by stable or conditional expression of a dominant-negative p100 mutant significantly reduced the incidence and growth rate of tumors.
|
19351823 |
2009 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, although p100 is highly expressed in a number of breast cancer cell lines, MHC Class I antigen expression was observed on all the cell lines we analysed and could be further induced by stimulation with the cytokines IFN-gamma or TNF-alpha.
|
9681829 |
1998 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, although p100 is highly expressed in a number of breast cancer cell lines, MHC Class I antigen expression was observed on all the cell lines we analysed and could be further induced by stimulation with the cytokines IFN-gamma or TNF-alpha.
|
9681829 |
1998 |
|
Neuromyelitis Optica
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 548 longitudinally assessed full-field visual evoked potentials (VEP) of 167 patients with NMOSD from 16 centers were retrospectively evaluated for changes of P100 latencies and P100-N140 amplitudes.
|
31796527 |
2020 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Increased P100 amplitude and latency may reflect reduced amygdala volume and disruptions in the visual system, while decreased N170 and increased VPP amplitudes may reflect impaired perceptual processing, mitigated by a greater involvement of prefrontal areas for task performance in AD.
|
31401490 |
2019 |
|
Phenylketonurias
|
0.010 |
Biomarker
|
group |
BEFREE |
The findings indicate that DHA supplementation in PKU patients from 2 weeks to 47 years of age improves DHA status and decreases visual evoked potential P100 wave latency in PKU children from 1 to 11 years old.Neurocognitive data are inconclusive.
|
31284588 |
2019 |